| Literature DB >> 33520728 |
Yang Wu1, Chun Zhang1, Kuirong Jiang2, Jens Werner1,3, Alexandr V Bazhin1,3, Jan G D'Haese1.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells (PSCs), the major producers of extracellular matrix (ECM), drive the severe stromal/desmoplastic reaction in PDAC. Furthermore, the crosstalk among PSCs, pancreatic cancer cells (PCCs) as well as other stroma cells can establish a growth-supportive tumor microenvironment (TME) of PDAC, thereby enhancing tumor growth, metastasis, and chemoresistance via various pathways. Recently, targeting stroma has emerged as a promising strategy for PDAC therapy, and several novel strategies have been proposed. The aim of our study is to give a profound review of the role of PSCs in PDAC progression and recent advances in stroma-targeting strategies.Entities:
Keywords: pancreatic ductal adenocarcinoma; pancreatic stellate cells; stroma-targeting strategy; tumor microenvironment; tumor therapy
Year: 2021 PMID: 33520728 PMCID: PMC7841014 DOI: 10.3389/fonc.2020.621937
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244